Overview

Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric Cancer

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To determine the quality of life in patients with gastric cancer who receive combination treatment with docetaxel and capecitabine. Secondary endpoints are time to progression, overall response rate and overall survival. Study treatment will continue until disease progression or unacceptable toxicity.

Phase:

Phase 2

Details

Lead Sponsor:

University of Turku

Collaborator:

Sanofi

Treatments:

Capecitabine
Docetaxel